It wouldn't be a surprise for there to be a difference in focus between the large academic/researcher led organisations and their conferences, and the more business oriented focus of a commercial conference organiser. "Show me the money".
This conference is titled as the "Glioblastome Drug Development Summit". "The Only Industry-led Forum Focused on Accelerating the Practical Translation & Clinical Development of Meaningful Therapies for the Treatment of Glioblastoma & Other Life Threatening CNS Tumors".
Key highlights of the conference include Funding. "Unpack how drug developers and funders can work together to drive glioblastoma research forward. Together the Sontag Foundation, National Brain Tumor Society, OrbiMed Advisors, The Branta Group, JP Morgan, The Invus Group, RA Capital Management and more, will facilitate important conversations about key considerations for nuances when it comes to glioblastoma treatments and lay out the different options available for financing GBM research."
I guess that we will find out well before then (tomorrow?), what the future path for Kazia will be.
Its also interesting to see that JG and Kazia have a significant profile at this conference. While the market appeared to write Kazia off after Paxalisib didn't move to the 2nd phase of the GBM Agile trial, plenty of other people still have time and space for its future, and may be interested in the recent painful experience of Kazia.
KZA Price at posting:
13.5¢ Sentiment: Hold Disclosure: Held
